Meeder Asset Management’s Filana Therapeutics FLNA Stock Holding History

Meeder Asset Management’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-300	Closed	-$13K	–	1765
2022 Q3	$13K	Hold	300	–	–	﹤0.01%	1240
2022 Q2	$8K	Hold	300	–	–	﹤0.01%	1463
2022 Q1	$11K	Buy	+300	New	+$12.7K	﹤0.01%	1520
2021 Q4	–	Sell	-1,899	Closed	-$117K	–	2119
2021 Q3	$117K	Buy	+1,899	New	+$158K	0.01%	861

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCM

Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Meeder Asset Management's FLNA Position: Q4 2022 in Review

Meeder Asset Management sold out of Filana Therapeutics (FLNA) in Q4 2022, closing a stake of 300 shares — an estimated $13K sold.

Meeder Asset Management first reported a position in FLNA in Q3 2021 and held it in 4 quarters. The position peaked at $117K in Q3 2021. 153 funds tracked by Wall St. Rank hold FLNA as of Q4 2022.

Meeder Asset Management reported no remaining Filana Therapeutics position as of Q4 2022 after selling out during the quarter.
Meeder Asset Management sold 300 Filana Therapeutics shares in Q4 2022, an estimated $13K.
Meeder Asset Management first reported a position in Filana Therapeutics in Q3 2021 and held it in 4 quarters.
Meeder Asset Management's Filana Therapeutics position peaked at $117K in Q3 2021.
153 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2022.

Based on Meeder Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.